For more than three decades, the annual Miami Breast Cancer Conference (MBCC) has brought together surgical, medical and radiation oncologists and the institutions and innovators that support them to advance all aspects of patient care in a rapidly changing environment.
MarginProbe is proud to be part of this year’s gathering at MBCC 2017. Advancing the standard of care for breast cancer patients through MarginProbe’s RF spectroscopy platform proven to help surgeons identify positive margins real-time during the initial lumpectomy procedure. We look forward to reconnecting with colleagues and creating new relationships with the surgeons on the front lines of care for breast cancer patients next week in Miami.
“After looking at our preliminary data we’ve found MarginProbe has significantly reduced our incidence of a positive margin. That means that I’m taking patients much less frequently back to the operating room for re-excisions now. In fact, with our first 36 cases using MarginProbe, we looked at our data and, our re-excision rate was 2.8%, which is far, far less than what you’d expect.” Dr. Jeffrey Falk, St. John Providence
“I use MarginProbe right in the operating room,” said Dr. Friedlander. “If it tells me I need to remove additional tissue from any of those edges on the tissue, we can do it right at that time. This significantly increases the chances of getting good margins on the first surgery. I’ve definitely been able to save patients from a second surgery using MarginProbe, no question.” Dr. Melanie Friedlander, South Bay Surgeons
Access more physician perspectives here.
Sessions that have our attention
- Thursday, March 9, 2:25 p.m. – Update on Margin Definition in DCIS with Elizabeth Mittendorf, MD, Ph.D.
- Friday, March 10, 9:00 a.m. – SystHERs: Lessons from Real-World Patients with HER2+ Metastatic Breast Cancer
- Saturday, March 11, 4:25 p.m. – Value Comparisons of Local-Therapy Treatment Approaches in Early-Stage Breast Cancer.
Access the full Miami Breast 2017 conference program here.
If you would like to learn more about MarginProbe and RF spectroscopy’s capability to reduce re-excisions for breast cancer patients or what the future of our technology holds for biopsy in breast cancer and other indications, contact email@example.com to arrange a meeting onsite at Miami Breast 2017 or stop by booth #30.